Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho
- Acadia Pharmaceuticals price target lowered to $31 from $33 at JPMorgan
- ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights
- ACADIA Pharmaceuticals: Strong Growth Prospects and Strategic Positioning Justify Buy Rating